http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Aug 2026 07:30:19 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html <p>Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.</p> <p>The offering consisted of 3,333,334 units priced at $0.15 per unit. Each unit includes one common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, expiring Aug. 18, 2029.</p> <p>The investor is Michael W. Porter, Founder and Managing Partner at PG Equity Group I, LLC. Porter previously co-founded Covis Pharma Group, where he served as CEO. He currently serves as Executive Chairman of AltaNova http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html Wed, 19 Aug 2026 07:30:19 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html <p>Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.</p> <p>The offering consisted of 3,333,334 units priced at $0.15 per unit. Each unit includes one common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, expiring Aug. 18, 2029.</p> <p>The investor is Michael W. Porter, Founder and Managing Partner at PG Equity Group I, LLC. Porter previously co-founded Covis Pharma Group, where he served as CEO. He currently serves as Executive Chairman of AltaNova http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html Wed, 19 Aug 2026 07:30:19 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html <p>Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.</p> <p>The offering consisted of 3,333,334 units priced at $0.15 per unit. Each unit includes one common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, expiring Aug. 18, 2029.</p> <p>The investor is Michael W. Porter, Founder and Managing Partner at PG Equity Group I, LLC. Porter previously co-founded Covis Pharma Group, where he served as CEO. He currently serves as Executive Chairman of AltaNova http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html Wed, 19 Aug 2026 07:30:19 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html <p>Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) has closed a non-brokered private placement raising $500,000, according to a press release from the cannabinoid-focused biopharmaceutical company.</p> <p>The offering consisted of 3,333,334 units priced at $0.15 per unit. Each unit includes one common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to purchase one additional common share at $0.20, expiring Aug. 18, 2029.</p> <p>The investor is Michael W. Porter, Founder and Managing Partner at PG Equity Group I, LLC. Porter previously co-founded Covis Pharma Group, where he served as CEO. He currently serves as Executive Chairman of AltaNova http://www.streetinsider.com/Equity+Offerings/Avicanna+closes+%24500%2C000+private+placement+with+pharma+investor/26947258.html Wed, 19 Aug 2026 07:30:19 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Press+Releases/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html <p align="justify">TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private placement.</p> <p align="justify">“Having spent my career building and investing in specialty-pharmaceutical and life-sciences platforms, I was impressed by Avicanna’s scientific depth, pharmaceutical operating discipline and clear focus on patient outcomes. The Company has assembled a differentiated platform spanning proprietary products, clinical and medical capabilities, international supply and patient-centered commercialization. I am pleased http://www.streetinsider.com/Globe+Newswire/Avicanna+Announces+Closing+of+Strategic+Non-Brokered+Private+Placement/26947253.html Wed, 19 Aug 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Press+Releases/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html <p align="center"><em>Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales</em><br/><em>QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured</em></p> <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce its financial results for Q2 2026, including the related financial statements and management’s discussion and analysis.</p> <p align="justify">“We are encouraged by the continued improvement in the fundamentals of our business http://www.streetinsider.com/Globe+Newswire/Avicanna+Reports+Q2+2026+Financial+Results/26933136.html Fri, 14 Aug 2026 18:30:00 -0400 0NN A.19244562 AVCN AVCNF O.37304256 O.51028198 http://www.streetinsider.com/Press+Releases/Avicanna+Introduces+QUIX%E2%84%A2+Rapid-Onset+Medical+Cannabis+Portfolio/26776703.html <p align="center"><em>Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats </em></p> <p align="justify">TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, today announced the introduction of its proprietary QUIX™-powered rapid-onset medical cannabis portfolio, with initial SKUs to be available across Canadian medical cannabis channels starting the third quarter of 2026 and additional SKUs planned for later in the year.</p> http://www.streetinsider.com/Press+Releases/Avicanna+Introduces+QUIX%E2%84%A2+Rapid-Onset+Medical+Cannabis+Portfolio/26776703.html Thu, 16 Jul 2026 07:30:00 -0400 0NN AVCN AVCNF O.37304256